> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly’s Taltz Approved for Plaque Psoriasis
- URL: https://www.fdaweb.com/lillys-taltz-approved-for-plaque-psoriasis/
- Published: 2016-03-22T12:00:00.000Z
- Updated: 2026-09-14T20:50:31.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135160

> FDA has approved an Eli Lilly NDA for Taltz (ixekizumab), indicated for treating adults with moderate-to-severe plaque psoriasis. The drug works by binding to a protein (interleukin (IL)-17A) that causes inflammation. “By binding to the protein, ixekizumab is able to inhibit the inflammatory response that plays a role in the development of plaque psoriasis,” an [FDA release](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htm?ref=fdaweb.com) says.  
>  
> Approval was based on safety and efficacy data from clinical trials with a total of 3,866 participants with plaque psoriasis who were candidates for systemic therapy or phototherapy. “The results showed that Taltz achieved greater clinical response than placebo, with skin that was clear or almost clear, as assessed by scoring of the extent, nature and severity of psoriatic changes of the skin,” the agency says.  
>  
> Because Taltz affects the immune system, a Medication Guide is required to inform patients that they may have a greater risk of an infection, or an allergic or autoimmune condition. “Serious allergic reactions and development or worsening of inflammatory bowel disease have been reported with the use of Taltz,” FDA adds.